CytomX Therapeutics Inc

Market cap: $137,495,481

Exchange: NAS

Sector: Health Technology

Share
Tweet

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Key Statistics

Company Name

CytomX Therapeutics Inc

Average Volume (10 days)

300,031

Average Volume (30 days)

735,996

Moving Average (50 days)

$2.18

Moving Average (200 days)

$1.59

Ex-Divided Date

n/a

Dividend Yield

0

P/E Ratio

-241.6441

Market Cap

137,495,481

Shares Outstanding

67,731,764

52-Week High Split Adjust Only

2.86

52-Week Low Split Adjust Only

1.04

Employee Count

157

Beta

0

Next Earnings Date

2024-05-07

TTM Dividend Rate Per Share

0

Price Changes

Past 5 days

-0.05%

Past 30 days

-0.19%

Past 3 months

0.28%

Past 6 months

0.66%

Past year

0.3%

Past 2 years

-0.24%

Past 5 years

-0.81%

Max % Change

-0.84%

PEER GROUP COMPARATIVE PERFORMANCE

NameTickerPrice/Sales (ttm)Price/Book (ttm)Forward P/EPEG RatioEV/Revenue
CytomX Therapeutics IncCTMX6.973.19-5.46.971.07
Peer AvgN/An/an/a-8.0n/an/a
Ocular Therapeutix IncOCULn/an/a-19.1n/an/a
Oncocyte CorporationOCXn/an/a-13.1n/an/a
Oragenics Inc.OGENn/an/an/an/an/a